How Analysts Feel About Soligenix Inc (NASDAQ:SNGX) After Decrease in Sellers?

June 10, 2018 - By Adrian Mccoy

Soligenix, Inc. (NASDAQ:SNGX) Logo

The stock of Soligenix Inc (NASDAQ:SNGX) registered a decrease of 4.18% in short interest. SNGX’s total short interest was 330,100 shares in June as published by FINRA. Its down 4.18% from 344,500 shares, reported previously. With 26,600 shares average volume, it will take short sellers 12 days to cover their SNGX’s short positions.

The stock increased 1.94% or $0.03 during the last trading session, reaching $1.58. About 8,264 shares traded. Soligenix, Inc. (NASDAQ:SNGX) has declined 32.77% since June 10, 2017 and is downtrending. It has underperformed by 45.34% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $13.83 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric CrohnÂ’s disease and acute radiation enteritis.

Another recent and important Soligenix, Inc. (NASDAQ:SNGX) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts …” on May 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: